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1. Introduction 
Increasing evidence supports both direct and indirect roles for retinal glia in the pathogene-
sis of glaucoma. To complicate these roles is the realization that glial activity can be both 
beneficial and detrimental to the survival of retinal ganglion cells (RGCs) and their axons. 
The contribution of glia to glaucoma pathogenesis also varies by compartment; glia in retina 
react differently to disease-induced stressors than glia in the optic nerve head or in the optic 
nerve. We will describe the evidence to date for the various roles of glia in each of these 
compartments. From this foundation, we have explored two hypotheses: whether 
manipulating gliosis can protect RGCs or their axons; and whether manipulating the anti-
oxidant supportive role of retinal glia could prevent RGC degeneration and preserve vision. 
Encouragingly, we have observed that retinal gliosis can be altered to positive effect for 
RGCs. Improving glial support of RGCs has also increased RGC and optic nerve axon 
survival.  
Glia greatly outnumber neurons in the CNS, but due to their reputation as secondary 
support cells, their study has lagged that of neurons. Within the retina, there are three types 
of glia: Astrocytes and Müller glia (the macroglia), and microglia. The Müller glia form the 
structural scaffolding of the retina, with endfeet that comprise both the inner and outer 
limiting membranes. The astrocytes reside among the retinal ganglion cells and their axons, 
while the microglia exist in non-overlapping tiled arrangements throughout the neuronal 
and synaptic layers of the inner retina (Bosco et al., 2011). Astrocytes and Müller glia 
provide homeostatic support to retinal neurons, including neurotransmitter and ion 
buffering, and anti-oxidant, nutrient and growth factor provision. Microglia, the resident 
immune cells, survey the retinal environment and respond to changes or threats. Müller 
glia, a macroglia subtype specific to the retina, serve all of the functions of parenchymal 
astrocytes, but with additional unique qualities such as transdifferentiation after specific 
kinds of injury (Bringmann & Reichenbach, 2001).  
Glia have garnered attention in the visual system through their emergence as fascinating 
arbiters of health and disease. Glia respond quickly to even the slightest homeostatic 
alterations, including pressure, electrical activity, infection, degeneration, and pH changes. 
Astrocytes and Müller glia undergo gliosis in response to many of these stimuli, a cellular 
hypertrophy that includes, but is not limited to, upregulating the intermediate filament 
proteins glial fibrillary acidic protein (GFAP) and vimentin. GFAP expression is always 
apparent in astrocytes, but Müller glia only express this intermediate filament in times of 
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stress (Kim et al., 1998). In some contexts, gliosis is accompanied by proliferation, but not in 
glaucoma. Of the glia subject to review here, only microglia proliferate in the DBA/2J 
murine model of glaucoma (Inman & Horner, 2007). Gliosis and the accompanying 
hypertrophy rearranges glial processes which can change glial connectivity and position. 
Microglia responding to environmental change often increase their secretion of matrix 
metalloproteinases (MMPs) and become motile, retracting processes and upregulating their 
expression of Iba1, a Ca2+-binding protein (Ito et al., 1998;  Bosco et al., 2008). Gliosis and 
microglial response are the earliest signs of pathology in glaucoma models that include 
intraocular pressure (IOP) increase (Inman & Horner, 2007;  Bosco et al., 2011). Increased 
IOP, like age, is a major risk-factor in developing glaucoma (Flanagan, 1998). Glia possess 
mechanoreceptors that could transduce the pressure signal for the retina (Gottlieb et al., 
2004). Some mechanoreceptors flux ions and likely initiate signal transduction that can lead 
to changes in glial production of intermediate filaments (GFAP, vimentin) and 
proteoglycans of extracellular matrix.  
Both astrocytes and Müller glia manage glucose metabolism, maintain the blood-retinal-
barrier, control ion and water homeostasis (Bringmann et al., 2006), and contribute to signal 
processing by recycling neurotransmitters and modulating neuron excitability (Stevens et 
al., 2003). Fundamental to the role of retinal glia is their exchange of substrates (pyruvate, 
glutamine) and their uptake of byproducts (glutamate, CO2) from neurons. Retinal glia often 
rely on anaerobic glycolysis which generates lactate; conversion of lactate to pyruvate then 
release from the glia via a monocarboxylate transporter, MCT2 (Lin et al.,1998) supplies 
neurons that take up the pyruvate and use it as a substrate in their own Krebs cycle. Like 
astrocytes, Müller glia also have glycogen deposits (Kuwabara & Cogan, 1961) that could 
provide a ready substrate during ischemia or glucose shortage.  
Of the several glutamate transporters identified in the CNS, retinal astrocytes and Müller 
glia primarily express GLAST (glutamate-aspartate transporter). The importance of 
glutamate transport in retinal glia extends beyond managing neurotransmitter levels in the 
extracellular milieu. Glutamate is an important stimulator of glycolysis in glia, via its co-
transport of Na+. In addition, glutamate, through the glial enzyme glutamine synthetase, 
gets converted to glutamine in glia, which then provides the glutamine to neurons for their 
production of glutamate and GABA (Pow & Crook, 1996). More important, however is the 
use of glutamate in the production of glutathione (GSH). This ubiquitous and quickly 
metabolized anti-oxidant is present in high concentrations in the astrocyte (up to 20mM) 
and released to the extracellular space. Once there, a glia membrane-bound ectoenzyme, Ǆ-
GT (Ǆ-glutamyltranspeptidase), breaks GSH into the cysteine-glycine dipeptide that can be 
taken up by neurons. This reaction is key because neurons maintain GSH at low levels in the 
cytoplasm (<1mM) and they cannot import it directly. Neurons require GSH to reduce side-
products of oxidative phosphorylation and detoxification pathways. The cysteine-glycine 
precursors for GSH are provided to neurons solely by astrocytes or Müller glia. Mechanisms 
of neurodegeneration related to glutamate handling and oxidative stress have been 
implicated in glaucoma, discussed in greater detail below.  
In this chapter, we review the role of glia by compartment of the visual system— retina, 
optic nerve head (ONH) and optic nerve (ON)— which encompass the potential sites of 
glaucoma initiation and progression. Astrocytes and microglia appear in each compartment 
while Müller glia are confined to the retina. The overlapping function of astrocytes and 
Müller glia reinforces common mechanisms for disease pathogenesis across visual system 
compartments; however, the unique environment in each compartment allows for distinct 
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causes and consequences of disease-related pathology. The various environments and 
stresses experienced by glia demand that we understand the time line of glial activation and 
find ways to manipulate that activation for RGC neuroprotection. Once we have discussed 
the mechanisms of glaucoma involving glia by compartment, we review the methods we 
have used glia to limit glaucoma pathology and protect RGCs and visual function.   
2. Retina 
Glaucomatous changes that result in RGC death occur in the retina. This general hypothesis 
for the pathogenesis of glaucoma draws strength from the fact that the retina contains the 
RGC somas and the glia that support them. The intraocular pressure (IOP) increases that 
pose a risk factor for glaucoma translate directly into key concerns for the RGCs in the 
retinal compartment. 
2.1 Astrocytes 
Astrocytes in the retina migrate in from the optic nerve as the retina develops (Huxlin et al., 
1992). Likely a reflection of their role in the blood-retinal-barrier, astrocytes are only present 
in the retinas of mammals with vascularized retinas (Stone & Dreher, 1987). They form a 
syncytium across the nerve fiber layer with processes that extend into the ganglion cell 
layer. Astrocytes ensheath RGC axons and have processes that converge on the initial 
segments of RGCs (Hollander et al., 1991). In places where vessels and axon bundles 
prevent Müller glia endfeet from forming the glia limitans of the inner limiting membrane, 
astrocytes extend the glial coverage over both vessels and axon bundles. Adherent junctions 
form between astrocytes and Müller glia, but gap junctions form only between astrocytes, 
never between astrocytes and Müller glia. The glial sheaths around RGCs are primarily 
comprised of Müller glia processes, though the occasional astrocyte process has been 
observed. Astrocytes (but not Müller glia) have processes that contact node-like 
specializations of RGC axons (Hollander et al., 1991). In human retina, there is limited 
astrocyte support in the macula, the region of tightly-packed multi-layered RGCs 
responsible for central high resolution vision. Vasculature also avoids this region; these facts 
have implications for glaucoma pathogenesis since the arcuate pattern of RGC loss in 
human glaucoma follows the arc of vessels and astrocytes beyond the macula (Araie, 1995).  
Astrocytes respond to even subtle changes in retinal homeostasis in ways that can be 
protective or detrimental. The most overt response of astrocytes to glaucoma in the retina is 
gliosis, which includes hypertrophy of the astrocytic cytoskeleton along with various context 
dependent changes in gene expression and astrocyte function. In some regions of the CNS, 
gliosis includes astrocyte proliferation and migration, but gliosis in glaucomatous retina is 
simply reactive (Inman & Horner, 2007). As RGCs die in glaucoma, hypertrophied astrocyte 
and Müller glia processes fill in the empty spaces. Increased proteoglycan production 
concomitant with GFAP and vimentin over-expression occurs in the DBA/2J mouse retina 
with early glaucoma (Figure 1). These proteoglycans, important to retinal development for 
neural patterning (Brittis et al., 1992), significantly inhibit axon growth or cellular migration 
when re-expressed (Inatani et al., 2000;  Inman & Horner, 2006). Proteoglycan deposition 
restricts the ability of the retina to engage in any endogenous repair. Two signal transduction 
pathways, the JAK/STAT and NFκB, have been implicated in the reactive gliosis observed in 
retinal astrocytes and Müller glia. Astrocytes in the DBA/2J mouse retina express STAT3 and 
phosphorylated STAT3 protein at higher levels as glaucoma progresses (Lupien & Horner, 
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2007).  Retinal astrocytes and Müller glia in vitro upregulate GFAP expression through the 
STAT3 pathway, as determined by increased GFAP expression with the addition of the STAT3 
activators ciliary neurotrophic factor (CNTF) or leukemia inhibitory factor (LIF) (Lupien et al., 
2008). GFAP expression in retinal glia decreased when inhibitors of NFκB were introduced 
four weeks after glaucoma induction (Lupien et al., 2009).  We have manipulated these 
pathways to understand the role of gliosis in glaucoma (see below). 
 
 
Fig. 1. A. Western blot of whole retina from DBA/2J mice from 2 to 6 months of age shows a 
significant increase in GFAP and CSPG expression concomitant with early increases in IOP 
(5-6 months of age, p<0.05). B & C. Immunolabeling of retina with antibodies against CSPG 
(green) and GFAP (red) show significant increases in GFAP expression in astrocytes of the 
nerve fiber layer (NFL) and significant upregulation of CSPG in Müller glia endfeet when 
comparing 4 month (B) and 8 month (C) DBA/2J retinal sections. Arrowheads point to 
Müller glia somas expressing CSPG in the inner nuclear layer (INL) in c’ and arrows point to 
GFAP expression in Müller glia processes (c’’) Scale bar=50 microns. repair.  
Retinal astrocytes release cytokines and chemokines in response to various stimuli, and 
changes in many of these signaling molecules have been observed in glaucoma. Astrocytes 
decrease their release of IL-6 when cultured under hydrostatic pressure, a condition 
designed to recapitulate the increased IOP observed in glaucoma (Sappington & Calkins, 
2006). Lower IL-6 expression may be detrimental to cell survival in retina because astrocyte-
derived IL-6 has been shown to regulate expression of metallothionein I and II, potent anti-
oxidants in the CNS (Penkowa et al., 2003). RGCs import astrocyte-derived metallothioneins 
through their megalin receptors; their import has been associated with subsequent axon 
regeneration (Chung et al., 2008). Regardless, IL-6 activates astrocyte gliosis through the 
activity of the JAK/STAT pathway, a potentially autocrine mechanism that may be helpful 
or detrimental depending on the context and timing of activation.  
Analysis of human glaucoma retina shows mRNA and intense immunolabel for TNFǂ in 
glia—likely both astrocytes and Müller cells, while the TNF-R1 was observed primarily on 
RGCs (Tezel et al., 2001). TNFǂ is a pro-inflammatory cytokine that can be released by 
microglia, astrocytes or Müller glia, and its effect depends upon the intracellular signals 
induced after binding to the TNFǂ-R1 or 2. For example, the TNFǂ-R1 receptor has a cell 
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death domain that promotes apoptosis, but only if NFκB anti-apoptotic mechanisms are also 
inhibited (Kraft et al., 2009). TNFǂ binding that leads to NFκB nuclear translocation enables 
transcription of inhibitors of apoptosis, thereby promoting cell survival (Beg & Baltimore, 
1996). Robust and sustained activation of JNK, which occurs when NFκB is suppressed, 
would indicate the TNFǂ-R1 directed apoptosis as opposed to survival. One model of 
experimental glaucoma found no evidence of JNK activation in RGCs or other cells of the 
retina (Levkovitch-Verbin et al., 2005), while JNK expression was observed in RGCs from 
glaucoma donor eyes, though the timing or persistence of expression is unknown (Tezel et 
al., 2003). TNFǂ-R1 can also activate cell protective heat shock proteins such as hsp70 in 
response to cellular stress (Heimbach et al., 2001), and this activity involves cross-talk with 
NFκB. TNFǂ represents just one signaling system between glia and neurons with finely-
tuned, context-dependent effects on RGC survival. TNFǂ undoubtedly can cause RGC 
apoptosis, but for which cells and when, and in which glaucoma-related contexts, remains a 
topic of active investigation.  
Astrocytes that surround synapses actively modulate synaptic activity in a Ca2+-dependent, 
glutamate mediated way (Jourdain et al., 2007). Early studies showed how the amplitude of 
Ca2+ waves moving through retinal astrocytes and Müller glia modulated the spike activity 
of RGCs (Newman & Zahs, 1998). Since glutamate antagonists reduce the inhibition of 
neuronal activity associated with glial Ca2+ waves, inhibition is likely mediated by 
inhibitory interneurons stimulated by glutamate release from glial cells. In the 
hippocampus, TNFǂ has been shown to regulate the glial release of glutamate that can 
escape glial reuptake and bind to neuronal NMDA receptors (Santello et al., 2011). TNFǂ 
improvement of glutamate exocytosis from astrocytes could be quite detrimental if the 
transport mechanisms to prevent glutamate RGC overstimulation are compromised. On the 
other hand, we have already outlined how loss of TNFǂ could limit the ability of astrocytes 
to support activity-dependent RGC survival. Well-timed glutamate release from glia 
activates glutamate transporters, potentially extending the interval of extracellular 
glutamate signaling. TNFǂ also works through the TNFǂ-R1 to increase AMPA-R insertion 
in the post-synaptic membrane. This multi-pronged modulation of glutamate signaling 
through TNFǂ significantly complicates our understanding of the role of TNFǂ in glaucoma. 
Müller glia, through their more intimate association with retinal synapses in which TNFǂ 
modulation of glutamate release would occur, will be the object of intense study of these 
phenomena.  
TNFǂ contributing to glutamate dysregulation implicates glutamate-induced excitotoxicity 
as a glial-related mechanism of glaucoma. Evidence for neurotoxic levels of glutamate has 
been observed in the vitreous of canines (Brooks et al., 1997) but not in monkeys (Carter-
Dawson et al., 2002) with induced glaucoma. However, focal depletion of glutamate in 
glaucomatous canine retina occurred concomitant with significantly lower levels of 
glutamine and glutamine synthetase (GS) (Madl et al., 2005;  Chen et al., 2008). Reduced 
glutamate disrupted important anti-oxidant systems, making oxidative stress secondary to 
glutamate dysregulation a potential mechanism of RGC loss in glaucoma. In support of this 
concept, anti-oxidant treatment ǂ-luminol restored glutamate, glutamine and GS levels and 
protected RGCs in the DBA/2J mouse model of glaucoma (Gionfriddo et al., 2009). Further 
detail regarding the role of oxidative stress appears in the Müller glia section below.  
In a microarray study that compared 3 and 8-month retinas from DBA/2J mice prior to 
outright glaucoma, a few of the mRNAs that underwent the greatest decrease were 
members of the crystallin family (Steele et al., 2005), a group of proteins with diverse 
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function but primary expression in the lens. The ǃA3/A1crystallin subtype, which was 
down 2-fold in 8-month DBA/2J, is also expressed in retinal astrocytes. Elimination of 
ǃA3/A1crystallins results in structural and functional defects in astrocytes that lead to 
abnormalities in vascular development and maturation (Sinha et al., 2008). Though these 
observations were made in young knockout mice, the implications of eliminating an 
astrocyte-derived vascular modulator in the DBA/2J glaucoma mice could have a 
significant effect on retinal function and RGC survival. Autoantibodies against ǂ-crystallin 
have been observed in normal-tension glaucoma patients, and these antibodies could cause 
apoptosis of RGCs in vitro (Tezel et al., 1998). These data as well as data described in the 
microglia section raises the possibility of an auto-immune component to glaucoma. 
Evidence for pathogenic glial interactions in glaucoma continues to mount.  
2.2 Müller glia 
Müller glia have overlapping roles with astrocytes, including redox homeostasis, 
maintenance of extracellular milieu through ion buffering and growth factor provision. 
However, by virtue of their role in retina structure, their contact of all retinal neurons, and 
their anatomical link between the vitreous of the inner retina and the pigment epithelium of 
the outer retina, Müller glia form a functional unit with a much more critical role to play in 
retina than astrocytes. Müller glia contribute more to the glia limitans and to wrapping cell 
somas in the inner retina than do astrocytes (Hollander et al., 1991). Through their 
expression of myriad receptors, ion channels, and transporters, Müller glia engage in 
extensive interplay (energetic and signaling) with their neuronal neighbors (Bringmann et 
al., 2006).  
The response of Müller glia to glaucomatous changes resembles that of astrocytes in that 
many activities are neuroprotective, but these macroglia can also severely damage the retina 
through the release of cytokines, nitric oxide, and proteoglycans or by failing to release 
growth factors. Beyond the non-specific responses to retinal injury which include 
upregulation of GFAP, vimentin (Bringmann & Reichenbach, 2001) and activation of the 
extracellular signal-regulated kinases (ERKs) (Tezel et al., 2003),  Müller glia have specific 
responses like upregulation of glutamine synthetase (GS) by mRNA and protein, which we 
have observed in the DBA/2J mouse retina at ages of accelerating RGC loss (10 months; see 
Figure 2). A similar upregulation of GS expression occurs in hepatic retinopathy where the 
GS detoxifies the retina of accumulated ammonia (Reichenbach et al., 1995). Upregulation of 
GS in Müller glia is neuroprotective against glutamate neurotoxicity (Gorovits et al., 1997), 
suggesting that the increased expression in DBA/2J retina may be a protective mechanism. 
As noted in the retinal astrocyte section, changes in GS have implications for managing 
oxidative stress and maintaining appropriate glutamate levels in retina.  
A strong neuroprotective role for Müller glia emerges in their management of the 
neurotransmitter glutamate. Müller glia use GLAST to efficiently move glutamate from the 
extracellular space in the course of normal retinal function but also in pathological 
conditions such as ischemia, a proposed contributor to the mechanism of glaucomatous 
damage. Patients with primary open angle glaucoma had glial activation that correlated 
well with vascular dysregulation (Grieshaber et al., 2007), a potential source of retina 
ischemia. Blocking GLAST or GLT-1 in the retina of normal rats led to glutamate increases 
and RGC death (Vorwerk et al., 2000), establishing that RGCs are sensitive to excitotoxicity. 
While Müller glia endeavor to maintain signaling homeostasis, RGCs do not necessarily sit 
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passively by: RGCs expressed one isoform of the GLT-1 transporter (GLT-1c) upon 
induction of glaucoma in the rat eye (Sullivan et al., 2006). This unusual expression might be 
a protective response to increases in extracellular glutamate. GLAST can reverse glutamate 
and aspartate transport when extracellular K+ concentration is high, as would be the case 
with high neuronal activity or Müller glia depolarization (Marcaggi et al., 2005). However, 
an electrophysiological analysis in the DBA/2J mouse model of glaucoma determined that 
neither membrane currents nor membrane potentials were altered in the Müller glia in mice 
with clear glaucoma pathology (Bolz et al., 2008). Evidently, concrete evidence for 
excitotoxicity in the glaucomatous retina is elusive; the evidence for oxidative stress as a 
driver in glaucoma, which can be secondary to glutamate dysregulation, is much stronger.  
 
Fig. 2. A. Glutamine synthetase (GS) mRNA in whole retina from DBA/2J mice from 3 to 10 
months of age, as percent of control (3 month levels). GS mRNA levels peak at 8 months, 
coincident with significant gliosis but prior to significant RGC loss. B. GS protein levels in 
whole retina from DBA/2J mice from 3 to 10 months of age. The protein levels were 
normalized to ǃ-actin. GS peaks at 10 months (p<0.05) when RGC loss is accelerating. 
Retinal glia have a fundamental role in maintaining redox homeostasis so are equipped with 
the tools to resolve redox imbalance. Oxidative stress occurs when reactive oxygen species 
(ROS) creation outpaces its clearance by anti-oxidant enzymes and compounds in a cell. 
Oxidative stress can result from exposure to stimuli that range from environmental toxins, 
infection and energy dysregulation to ischemia; it has been implicated in several 
neurodegenerative diseases, including glaucoma (Gmitterova et al., 2009). Resolution of 
oxidative stress can halt neurodegeneration (De Luca et al., 2008). As will be discussed at 
length in the section on optic nerve head, increased IOP can affect blood flow to the retina. 
Lack of nutrient delivery and waste removal via the circulation leads to ischemia. Müller 
glia upregulate iNOS in times of ischemia and the subsequent NO can dilate blood vessels 
(Goldstein et al., 1996), but NO can also be quickly converted to peroxynitrite that can attack 
proteins. Protein thus nitrated can disrupt normal cellular function and lead to increased 
energy demand. ATP energy in the CNS comes from glycolysis or oxidative 
phosphorylation. Non-reduced diatomic oxygen (O2·), known as superoxide anion, is the 
primary mitochondrial reactive oxygen species (ROS) generated from oxidative 
phosphorylation (Skulachev, 2006). Other ROS can be derived from superoxide production. 
ROS attack glutamate transporters on redox-sensing cysteine residues (Aschner, 2000), 
leading to higher extracellular glutamate, lower glutamine (and therefore, glutathione) 
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production as well as compromised energy availability, a dangerous feedback loop. The loss 
of the anti-oxidant glutathione hinders the cell's ability to limit ROS damage. Cellular 
components accumulate ROS-related changes (oxidation, nitration, lipidation) and cease to 
function. As a sign of extreme distress, Müller glia exposed to ROS express major 
histocompatibility class II molecules, allowing these glia to present antigen and T cells to 
create antibodies against the presented protein (Tezel et al., 2007). Autoantibodies appear in 
the serum of glaucoma patients (see microglia section below). Oxidative stress can be 
initiated in several ways; it is certainly a secondary degenerative process in glaucoma, but it 
has the ability to amplify and extend damage at every level of cellular regulation, making it 
a formidable foe.  
Müller glia from human glaucoma eyes showed increased levels of advanced glycation end 
products (AGE), an inflammatory stimulant, as well as the receptor for advanced glycation 
end products (RAGE) (Tezel et al., 2007). Müller glia express proinflammatory cytokines IL-
6 and TNFǂ (Tezel & Wax, 2000) in response to AGE exposure. TNFǂ release has been 
shown to impact the blood-retinal-barrier through increased vesicular transport of serum 
proteins by vascular endothelial cells. Serum proteins accumulate in Müller glia, 
perivascular microglia and pericytes after TNFǂ exposure, suggesting that these glia protect 
the retina  by acting as secondary barriers (Claudio et al., 1994). However, Müller glia are 
just as likely as retinal microglia and astrocytes to be a source of the TNFǂ. Similarly to 
astrocyte-derived TNFǂ, Müller glial TNFǂ can dictate cell death or survival based on the 
complement of receptors and second messenger systems available to it.   
2.3 Microglia 
Microglia function in environment surveillance, synapse elimination, cytokine/chemokine 
release, innate immunity and debris clean-up. The release of specific cytokines and synapse 
elimination are two mechanisms of glaucoma in which microglia would play a significant 
role, possibly driving pathogenesis. In order to implicate microglia in the development of 
glaucoma, one research group used minocycline to reduce microglial activation and 
document changes in glaucoma disease progression. A significant decrease in microglial 
activation occurred with minocycline treatment, as shown through morphology and gene 
expression, and there was significant improvement of retrograde transport in RGC axons 
(Bosco et al., 2008). Minocycline inhibits the expression of NOS (Amin et al., 1996) and exerts 
a stimulus-dependent decrease or increase the production of IL-6 through TNF-ǂ 
(Kloppenburg et al., 1996). Microglia in DBA/2J mouse retina have been shown to release 
the cytokine IL-6. These observations suggest protection of RGCs by decreasing microglial 
activation in glaucomatous retina, but it does not rule out a contribution of astrocytes, 
Müller glia or even neurons due to the systemic delivery of the minocycline treatment.  
Microglia increase their expression and release of IL-6 when cultured under hydrostatic 
pressure, conditions meant to mimic the retina at increased IOP (Sappington & Calkins, 
2006). Microglia-derived IL-6 rescued RGCs cultured under hydrostatic pressure from death 
(Sappington et al., 2006). Interestingly, retinal microglia express TRPV channels, cation-
selective transient receptor potential vanilloid-1 receptors sensitive to mechanical stimuli 
like pressure (Sappington & Calkins, 2008). IL-6 release from microglia under pressure 
required Ca2+ increase, mediated by both intracellular ryanodine receptors and TRPV 
channels (Sappington & Calkins, 2008). The same group also demonstrated that IL-6 
increases were preceded by sustained NFκB nuclear translocation, suggesting that NFκB 
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drives IL-6 changes in retinal microglia (Sappington & Calkins, 2006). Antagonism of Ca2+ 
release reduced IL-6 release and NFκB activation in retinal microglia. These findings reflect 
the complexity of glial response during disease circumstances; not only is IOP translated by 
glia in myriad ways, but those ways can be in opposition, depending on the glial subtype.   
Additional studies have underscored the complexity of glial-associated pathogenesis by 
showing the give and take of astrocytes and microglia. Astrocyte-derived signals (possibly 
ROS) initiated Nrf2 activity and expression of heme-oxygenase in microglia (Min et al., 
2006). Conditioned media from those astrocytes suppressed interferon-Ǆ (IFN-Ǆ)-induced 
ROS production, leading to reduced iNOS expression and NO release. These data illustrate 
the feedback loop of ROS production that exists between these glia. Feedback loops 
regulated by astrocytes in microglia work in reverse too:  Microglia can activate the Nrf2-
ARE (anti-oxidant response element) in astrocytes and change the redox level there.  
An autoimmune component to glaucomatous optic neuropathy has emerged from 
observations of serum autoantibodies against proteoglycans in open-angle glaucoma 
patients (Tezel et al., 1999), and against heat shock proteins (hsp) hsp27 and hsp60 (Wax et 
al., 2008) in patients with normal tension glaucoma (NTG). Microglia have a complex, 
context-dependent role in autoimmunity. They can express MHC class II proteins which 
allow them to present antigen. Their expression of Fas ligand (FasL), a cytokine in the TNF 
superfamily, leads to apoptosis in cells expressing the FasL receptor. Immunization of rats 
with hsp27 or hsp60 activated microglia and upregulated FasL receptor expression in RGCs 
and cells in the INL (Wax et al., 2008). Heat shock proteins are upregulated in times of stress 
and function as protein chaperones or assembly of protein complexes (Young & Elliott, 
1989). In NTG patients, antibody against hsp27 may reduce the ability of native hsp27 to 
stabilize the cytoskeleton, thereby initiating apoptosis in hsp27-expressing cells (Tezel & 
Wax, 2000). These data suggest that activated microglia could initiate apoptosis in cells 
targeted by autoantibodies. Conversely, the expression of FasL proteins by retinal microglia 
may be a mechanism of maintaining ocular immune privilege and avoiding damaging 
inflammatory reactions in the eye (Griffith et al., 1995) by inducing apoptosis of invading T-
cells. Ocular immune privilege certainly limits T-cell travel in the retina unless coincident 
with blood-retinal-barrier breach, a circumstance that has been demonstrated only in canine 
glaucoma that is secondary to uveitis (Reilly et al., 2005;  Mangan et al., 2007). Glaucoma 
experimental models that document persistent microglial activation do not also find T-cells 
(Ebneter et al., 2011). Glaucoma T-cell entry to the retina is receptor-mediated even in cases 
of clear autoimmune retinal pathological mechanisms such as in glaucomas secondary to 
sarcoidosis (Hamanaka et al., 2002) or B-cell lymphoma (Cockerham et al., 2000), in which T-
cell or B-cells were observed in Schlemm's canal and trabecular meshwork. Therefore in 
retina, these studies suggest microglia would be the primary agents of autoimmune-related 
FasL-induced apoptosis capable of dispatching significant numbers of RGCs. Further 
investigation into which cells present antigen, what comprises that antigen and which cells 
express the FasL receptor would improve our understanding of potential autoimmune 
processes in glaucoma. 
Based on evidence from innate immunity research, microglia and astrocytes coordinate 
management of synapses in the inner retina. The initiating member of the classical 
complement cascade, complement component 1q (C1q), coats dead cells, debris or 
pathogens and initiates a protease cascade that results in complement C3 deposition. C3 can 
activate receptors on microglia that signal the cells to phagocytose any C3-coated elements. 
Synapse elimination during CNS development proceeds by this mechanism (Stevens et al., 
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2007), with immature astrocytes signaling to RGCs to express C1q. Not normally observed 
in the adult retina, C1q is nevertheless upregulated in glaucomatous eyes (Steele et al., 2005;  
Stasi et al., 2006), suggesting that activated astrocytes have overcome their developmental 
limitations and released a factor to which the RGCs respond by making C1q. 
Immunolabeling of the inner plexiform layer where RGCs synapse with amacrine and 
bipolar cells shows C1q upregulation coincident with synapse loss (Stevens et al., 2007). An 
unknown stimulus triggers the astrocytic release of the factor that leads to C1q upregulation 
in the glaucomatous retina. Microglia respond by eliminating the targeted synapses, 
reducing RGC connectivity. Evidence for dendritic arbor shrinkage and loss (Weber et al., 
1998;  Pavlidis et al., 2003;  Shou et al., 2003) in glaucoma supports this mechanism of 
degeneration.  
A study in which a bone marrow transplant after irradiation rescued RGCs from cell death 
in the DBA/2J has intrigued many, and may be evidence for a vital role of microglia in 
glaucoma. Since microglia comprise the largest group of proliferating cells in the retina 
(Inman & Horner, 2007), the irradiation would have destroyed them and any endothelial 
cells. The bone marrow transplant repopulated the immune system and irradiation created a 
leaky blood-retinal-barrier, allowing peripheral immune cells to infiltrate. No one 
understands the mechanism of protection against optic neuropathy in this study, but the 
results highly suggest eliminating endogenous retinal microglia enabled RGC rescue 
(Anderson et al., 2005).    
3. Optic nerve head 
3.1 Locus of degeneration 
A long-held hypothesis of the mechanism of RGC damage in glaucoma states that 
compression and rearrangement in the lamina cribosa cribriform plates, the connective 
tissue collagen plates through which the ganglion cell axons pass to form the optic nerve, 
impinge upon the axons, disrupting axon transport to a degree that leads to axon 
degeneration and RGC death (Quigley & Addicks, 1981). Supportive evidence for this 
hypothesis includes failure of retrograde delivery of target-derived growth factors in 
monkey and rat glaucoma models (Pease et al., 2000;  Quigley et al., 2000) as well as the 
considerable extracellular remodeling that alters the lamina and deposes significant 
amounts of collagen and proteoglycans in humans (Tengroth & Ammitzboll, 1984;  Tengroth 
& Ammitzboll, 1984) and in experimental glaucoma models (Johnson et al., 1996). The optic 
nerve head (ONH) undergoes considerable deformation in response to the diurnal 
fluctuation in IOP, and these conformational changes impact both glia and RGC axons. 
There are several mechanosensitive receptors on ONH astrocytes that could respond 
directly to changes in IOP (Oh, 1997).  
Despite lacking a lamina cribosa, the DBA/2J mouse provides additional evidence for the 
optic nerve head as the site of initial damage in glaucoma. Fasciculated RGC axons travel 
through glial columns (glia lamina) in the mouse until myelination within the optic nerve. 
The glial columns are astrocytes arranged parallel to the axons and run caudal from the 
scleral boundary for about 200 microns (Howell et al., 2007), beyond which the ganglion cell 
axons become myelinated by optic nerve oligodendrocytes (May & Lutjen-Drecoll, 2002). 
Dystrophic neurites, with swollen and accumulated organelles and neurofilament 
breakdown, were observed in the glia lamina while the corresponding axons in the pre-
lamina and in the retinal nerve fiber layer were intact (Howell et al., 2007). It appears that 
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axons underwent degeneration as entire fascicles, leaving sectors of ganglion cells 
axotomized and destined for degeneration within the retina (Jakobs et al., 2005;  Howell et 
al., 2007). These data raise two interesting possibilities: for one, doubt is cast on the idea that 
the lamina cribosa pinches the axons to initiate glaucomatous degeneration; but secondly, 
the data implicates astrocytes in the lamina as prime drivers of pathology in this disease. 
The pattern of degeneration, that of ganglion cell loss in a pattern dictated by the position of 
axons lost, mirrors that observed in the human retina and proximal optic nerve. Astrocytes 
and microglia are the sole cell types in the lamina, so how might these cells initiate 
glaucoma? Recent evidence suggests mechanisms of action that include increased 
endothelin release, axon impingement from changes in extracellular matrix and astrocyte 
migration, oxidative stress from intermittent ischemia, and anterograde axon transport 
deficit of unknown etiology.  
3.2 ONH astrocytes 
As RGC axons undergo degeneration, the optic cup deepens, enabled by astrocyte 
remodeling and migration. The prelaminar portion of the optic nerve loses glial columns 
and astrocytes migrate between axon bundles (Hernandez & Pena, 1997). The ONH has both 
Type1A and Type1B astrocytes, distinguished primarily by the expression of NCAM in 
Type1B; both types express GFAP. Type1B astrocytes appear to be responsible for 
extracellular matrix production in ONH (Ye & Hernandez, 1995). Astrocytes depose new 
extracellular matrix (ECM) in the course of glaucoma development. Astrocytes isolated from 
the human optic nerve head upregulated their expression of neural cell adhesion molecule 
(NCAM) two-fold by 6h of exposure to 60mmHg hydrostatic pressure (Ricard et al., 2000). 
NCAM participates in cell anchoring, so documented changes in its expression in glaucoma 
(Ricard et al., 1999) suggest a potential point of intervention if astrocyte migration 
contributes to the incipient optic neuropathy. Integrins join GFAP and vimentin at focal 
adhesion complexes on astrocytes that connect the cells to ECM, giving them a role in cell 
migration and transmitting mechanical signals to the astrocyte (such as increased IOP). 
Integrins also undergo considerable changes in expression in glaucoma (Morrison, 2006). 
Altered ECM makeup means potential loss of compliance of this dynamic tissue.  
As demonstrated in the retina (see Figure 1), glia overexpress proteoglycans during gliosis 
in glaucoma. Serum autoantibodies obtained from patients with normal tension glaucoma 
and those with increased IOP bind to chondroitin sulfate and heparan sulfate 
glycosaminoglycans, proteins upregulated in the optic nerve head of glaucoma patient 
tissue (Tezel et al., 1999). However, chondroitin sulfate proteoglycan 4 (CSPG4) and CSPG1 
(aggrecan) mRNA stood out on one ONH astrocyte microarray for being downregulated 35-
fold and 29-fold, respectively in glaucoma patients (Hernandez et al., 2002). If there are 
feedback mechanisms that regulate proteoglycans, the mRNA downregulation might be a 
response to the persistence of the protein within the tissue. Optic nerve head astrocytes also 
degrade extracellular matrix as they migrate in vitro after exposure to hydrostatic pressure 
(Tezel et al., 2001).  
Astrocytes in the optic nerve head (and retina) express G-protein-coupled endothelin 
receptors ETA and ETB, as do retinal vessels. Endothelin, a vasoactive and neuroactive 
peptide, has been shown to produce optic neuropathy when injected intravitreally. Patients 
with primary open-angle glaucoma have significantly higher levels of aqueous humor 
endothelin than age-matched normal patients (Tezel et al., 1997;  Iwabe et al., 2010). 
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Endothelin leads to intracellular Ca+2 increases in astrocytes and can increase astrocyte 
hypertrophy and proliferation (Prasanna et al., 2003). This effect was mediated by the ETA 
receptor since it could be blocked by an ETA-specific antagonist. Ischemia and mechanical 
pressure can induce endothelin secretion from astrocytes. ETA has greatest affinity for ET-1 
and ET-2 while ETB has equal affinity for all three isoforms of ET (1, 2 and 3). Endothelin can 
disrupt anterograde axon transport, making its upregulation in optic nerve head astrocytes 
(even retinal astrocytes) an important potential mechanism of glaucoma. Key to 
understanding the role of endothelin is recognizing that it had effects on specific transport 
types and times; early after intravitreal injection of 2nM endothelin, it increased fast 
anterograde axon transport of tubelovesicles, but by 28h after injection, it decreased 
transport of mitochondria and decreased slow anterograde transport of cytoskeletal proteins 
at 4 days (Stokely et al., 2002). A straightforward mechanism for optic neuropathy initiated 
by endothelin would combine its vasoconstriction (through the ETA) that leads to ischemia 
with the energy dysregulation in RGC axons, a result of the ETB-mediated deficit in 
mitochondrial anterograde transport.  Not surprisingly, TNFǂ stimulates ET-1 release in 
ONH astrocytes exposed for 24h to hypoxia (Desai et al., 2004).  
Some of the genes downregulated in ONH astrocytes cultured from human glaucoma patients 
have negative ramifications for cell survival. The loss of glucose transporter mRNA (GLUT5) 
and monocarboxylate transporter (MCT3) (Hernandez et al., 2002) would challenge astrocytes 
to maintain energy levels and exchange pyruvate or lactate with neurons. Fuel energy 
dysregulation would negatively impact membrane potentials and therefore action potential 
propagation in the neighboring RGC axons. Axonal Na+ overload occurs when energy 
substrates  to decrease and Na+ initiates Ca2+ accumulation in the axon through reverse 
operation of the Na+/Ca2+ exchanger (Stys et al., 1992). Subsequent to Na+ overload, K+Cl- co-
transporters, with subtypes present on both astrocytes and axons, release K+ and Cl- from the 
axons, disrupting the Cl- gradients that contribute to resting optic nerve membrane potential 
(Malek et al., 2003)  Axons unable to conduct action potentials will fail to transmit the visual 
signal from RGCs to the target regions in brain. Energy depletion would be complete as ATP-
dependent processes such as axon transport would cease. This proposed mechanism supports 
many of the observations of generalized axon transport failure (Buckingham et al., 2008) or 
transport failure at the ONH (Minckler et al., 1977;  Quigley et al., 2000). However, important 
observations of axon transport deficit in the DBA/2J mouse model of glaucoma showed that 
axon transport in glaucoma fails first in the target regions of the RGC axons, the superior 
colliculus (Crish et al., 2010). There are many activity-dependent regulatory mechanisms that 
maintain synapses and transmit sustaining growth factors back to the RGC soma. One might 
anticipate loss of synaptic connections with axon conduction loss, though the authors were 
able to demonstrate in the DBA/2J that collicular synapses were intact despite lack of 
transport to the target (Crish et al., 2010). Certainly distal transport failure highlights the 
logistical difficulties that RGCs face in getting cargo to remote synapses and highlights a 
potentially novel mechanism of glaucoma pathology.   
Understanding the mechanism of optic neuropathy in glaucoma is complicated by the 
frequent overlap of expression and activation of potentially damaging intermediates by both 
astrocytes and microglia. Cytokines and chemokines expressed by glia have been implicated 
in neurodegeneration, and the feedback loops or escalation of inflammatory processes are 
difficult to tease apart. Astrocytes in human glaucomatous ONH express TNF-ǂ and its 
receptor, TNF-R1 (Yuan & Neufeld, 2000). Upregulation of TNF-ǂ and TNF-R1 occurred 
concomitant with increasing optic nerve degeneration; in severe glaucoma, TNF-ǂ and TNF-
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R1 were also expressed on activated microglia (Yuan & Neufeld, 2000). One consequence of 
TNF-R1 activation is NOS-2 induction, in both astrocytes and microglia (Neufeld, 1999). 
NOS-2 induction also occurs in reactive astrocytes from human ONH as a result of 
epidermal growth factor (EGF) receptor agonism (Liu & Neufeld, 2003). ONH astrocytes 
exposed to hydrostatic pressure showed increased EGF-R expression and phosphorylation, 
as did reactive, but not quiescent, astrocytes in human glaucoma ONH (Liu & Neufeld, 
2003). A microarray analysis of EGF-R activation in ONH astrocytes showed upregulation of 
many genes associated with astrocyte activation, including various proteoglycans, ETA, 
leukemia inhibitory factor (LIF), insulin-like growth factor (IGF), fibroblast growth factor 2 
(FGF-2), nerve growth factor (NGF), transforming growth factor- ǃ (TGFǃ) and tissue inhibitor 
of matrix metalloproteinase (TIMP) (Liu et al., 2006). Others have shown ONH astrocytes 
express TGFǃ (Pena et al., 1999) which can upregulate ECM molecule expression, both 
possibly as a result of EGF-R activation. These data suggest that EGF is a potent astrocyte 
activator, but ironically, many of the upregulated genes are growth factors which generally 
support cell survival. Seven months delivery of an EGF-R tyrosine kinase inhibitor or NOS-2 
inhibitor protected RGCs from cell death in a chronic rat model of glaucoma (Liu et al., 2006). 
The treatments sought to eliminate EGF-R activation and its target NOS-2 in astrocytes. Due to 
systemic delivery of the inhibitors, any cells with EGF-R would be antagonised, though the 
implication is that tempering glial reactivity protected RGCs from glaucoma-related cell death. 
However, RGC number and not function was the only outcome measure.   
3.3 ONH microglia 
Microglia are activated in glaucomatous human ONH (Neufeld, 1999) and very early at the 
ONH in chronic glaucoma models, indicating either an unusual responsiveness to stressors 
there or an initiation of degenerative processes (Bosco et al., 2011). Microglia often appear 
activated and in high numbers near the peripapillary chorioretinal region, a possible site of 
tenuous blood-retinal-barrier, and in close proximity to retinal vessels (Neufeld, 1999). 
These cells' position and activation state suggest interaction with the periphery; perhaps the 
observed autoantibodies against proteins found in the ONH are generated with the 
assistance of ONH microglia. Microglia in ONH of humans with glaucoma (but not 
controls) express TNFǂ, TGFǃ and shows signs of proliferation by being immunopositive for 
PCNA, the proliferating cell nuclear antigen (Yuan & Neufeld, 2001). Cytokine expression 
targets astrocytes, the primary cell type in the ONH besides microglia, and modulates many of 
the pathological processes already described. TNFǂ induces NOS-2 which leads to nitric oxide 
(NO) production in microglia. Microglia can affect axon transport of synaptic vesicle 
precursors by releasing nitric oxide (Stagi et al., 2005). This ability would be especially 
destructive in the ONH where the RGC axons do not have a protective myelin sheath and 
activated microglia have been observed very early in the DBA/2J mouse model of glaucoma 
(Bosco et al., 2011). Microglia constitutively express several matrix metalloproteinases (MMPs) 
that get upregulated with glaucoma progression. These enzymes can contribute to much of the 
documented tissue remodeling that occurs in the ONH. 
4. Optic nerve  
All glaucomas, regardless of etiology, share optic nerve (ON) degeneration. Despite this fact, 
the ON has not been a focus of research into the pathogenesis of glaucoma. This may change 
with recent evidence of phagocytic astrocytes and energy dysregulation in ON. 
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4.1 ON astrocytes 
Unlike in the retina, astrocytes proliferate in the glaucomatous optic nerve, as well as 
increase their expression of vimentin (Son et al., 2010). There are age-related changes in 
optic nerve astrocytes that likely alter their ability to function. One recent glaucoma 
hypothesis posits that phagocytic astrocytes in a particular region of the optic nerve, an area 
just rostral to the beginning of myelination (the myelination transition zone, or MTZ), 
become dysregulated. These phagocytic MTZ astrocytes express Mac-2 and upregulate it 
with IOP increase; the Mac-2 levels correlated with the number of RGCs with damaged 
axons in the retina (Nguyen et al., 2011). Spheroids in the MTZ contained Ǆ-synuclein; their 
numbers increased in DBA/2J mice with glaucoma. The MTZ astrocytes were observed with 
large, Ǆ-synuclein-positive axon inclusions within their cytoplasm (Nguyen et al., 2011). 
These data suggest that glaucoma might be a synucleinopathy, with the Ǆ-synuclein axon 
spheroids in the MTZ mimicking the ǂ-synuclein accumulations in Lewy bodies that 
contribute to cell death in Parkinson's disease. Immunolabeling for Ǆ-synuclein was 
observed in human optic nerve (on axons and GFAP+ astrocytes) from glaucoma patients 
(Surgucheva et al., 2002). In models of glaucoma, phagocytic astrocytes in the myelination 
transition zone (MTZ) may become hyperactive in a bid to control Ǆ-synuclein 
accumulation, or they may be responding to pressure signals that encourage hyper-
phagocytosis and lead to premature axon destruction.  
Also of note, one study of glaucomatous ON showed an inverse relationship between IOP 
and available ATP. Increased IOP correlated with significantly decreased ATP in ON (Baltan 
et al., 2010), suggesting a metabolic vulnerability in glaucoma. Given that astrocytes 
comprise 28 percent of the ON (Perge et al., 2009), it may be the case that ATP decrease 
occurs in ON astrocytes. This possibility, combined with the observation of Glut5 and MCT 
downregulation in ONH astrocytes (Hernandez et al., 2002) supports an astrocyte energy 
dysregulation mechanism of optic neuropathy. Efforts to resolve whether ATP decrease in 
extrinsic (astrocytes) or intrinsic (axons) to the ON in glaucoma continue.  
4.2 ON microglia 
Microglia also occupy non-overlapping areas in the optic nerve (ON). Microglia may have a 
role in the glaucomatous ON that resembles their function in the ONH. Microglia-derived 
TNFǂ recruited macrophages to the sciatic nerve during Wallerian degeneration (Liefner et 
al., 2000), in part by inducing MMP activity that allows migration of these cells to sites of 
debris. As discussed in the ONH section, TNFǂ figures prominently in the response of 
microglia to the increased IOP and intermittent ischemia that occurs at the ONH. In the 
glaucomatous optic nerve, microglia have been observed full of lipid droplets, the result of 
ingesting myelin debris (Figure 3), but only in ON undergoing significant degeneration.  It 
has yet to be determined if ON microglia have a role to play in glaucoma pathogenesis. 
5. Manipulating glia 
5.1 Intracellular pathways 
Manipulating gliosis is one strategy for diminishing any negatives, and improving upon any 
positive effects, of glial response on RGC survival and function in glaucoma. We have 
changed the course of gliosis in mice with glaucoma by manipulating two intracellular 
signaling pathways implicated in gliosis, the JAK/STAT and the NFκB pathways. In one 
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Fig. 3. Cross-sections of DBA/2J optic nerve at 3 months (left) and 12 months (right) shows 
green Iba1-positive microglia (arrows) filled with phagocytosed myelin debris (red) as 
labeled by a dye that stains lipid droplets (Oil Red O). Axons are labeled blue with an 
antibody against neurofilament-200 (NF-H) Scale bar=100 microns. 
transgenic mouse, STAT3 is knocked out in GFAP+ cells (Herrmann et al., 2008); in the 
other, NFκB in GFAP+ cells is prevented from translocating to the nucleus (Brambilla et al., 
2005).  
STAT3, a critical regulator of astrocyte intermediate filament upregulation and hypertrophy 
(Herrmann et al., 2008), transduces the intracellular signal for IL-6, CNTF and LIF, cytokines 
released after CNS injury. STAT3 has been observed in the nuclei of Müller cells, RGCs and 
astrocytes (Thanos & Naskar, 2004;  Wang et al., 2010). In general, STAT3 activation is 
present in neurons in the acute phase of neural tissue injury and in astrocytes during the 
chronic phase, though severe injury may disturb this distinction (Yi et al., 2007). 
Furthermore, contradictions about the protective nature of STAT3 activation abound. For 
example, Luo et al.,  found that inhibition of JAK/STAT promoted RGC survival and axon 
regeneration (Luo et al., 2007), while a separate study showed that activation of STAT3 
protected RGCs (Ji et al., 2004). In the former, RGC survival accompanied inhibition of 
macrophage recruitment, suggesting that JAK/STAT inhibition protected RGCs by 
preventing immune cell infiltration. To further clarify the role of STAT3, we subjected the 
GFAP+-STAT3-KO mouse (Herrmann et al., 2008) to the microbead occlusion glaucoma 
model (Sappington et al., 2009). The STAT3-KO had decreased GFAP and proteoglycan 
expression in retinal glial cells and optic nerve when compared to control. Moreover, RGCs 
were significantly spared from degeneration in the STAT3-KO mice (Lupien et al., 2010).  
NFκB is a transcription factor expressed in neuronal and glial cells (Kitaoka et al., 2006) that 
regulates the expression of genes involved in inflammation, cell survival and apoptosis 
(Hayden & Ghosh, 2004).  NFκB is multi-talented, able to upregulate anti-apoptotic factors 
but also activate pro-apoptotic pathways. This dual role is reflected in retinal research; for 
example, deletion of the p50 subunit of NFκB led to accelerated age-related RGC death 
(Takahashi et al., 2007). Also, ONH astrocytes from glaucoma patients express higher levels 
of NFκB mRNA and show greater nuclear translocation than controls (Agapova et al., 2006). 
Conversely, GFAP-IκBǂ-dn mice given retinal ischemia achieved significant survival of 
RGCs and reduction of pro-inflammatory gene expression (Dvoriantchikova et al., 2009). 
Our research would echo the latter findings in that we observe decreased retinal gliosis in 
vitro and in vivo by using NFκB inhibitors in a glaucoma mouse model (Lupien et al, 2009). 
By subjecting the GFAP-IκBǂ-dn mice to acute glaucoma, we also observed a significant 
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decrease of GFAP expression in retinal glial cells that coincided with RGC survival and 
improved visual function (unpublished data). 
5.2 Oxidative stress pathways 
Manipulating essential functions of glia can augment glial support of retinal neurons. One 
major glial support function is the management of retinal redox homeostasis. Through 
delivery of exogenous anti-oxidants or the manipulation of anti-oxidant pathways within 
the retina, we have altered the neural-glial interaction in a way that improves RGC survival 
and function. In many circumstances, retinal glia provide protection from oxidative stress 
through the ROS-mediated liberation of a transcription factor, Nrf2, that binds to the anti-
oxidant response element (ARE) (Itoh et al., 1999) and promotes the expression of anti-
oxidants such as heme-oxygenase, ceruloplasmin (Miyahara et al., 2003;  Lambert et al., 
2006), peroxiredoxin 1, catalase, glutathione peroxidase, superoxide dismutase and 
thioredoxin (Lee et al., 2003;  Kobayashi & Yamamoto, 2005). Nrf2 controls expression of 
genes encoding the catalytic (GCLC) and modifier (GCLM) subunits of glutamate-cysteine 
ligase, the rate-limiting enzyme in glutathione (GSH) biosynthesis (Wild et al., 1999). 
Glutathione is such an important component of redox homeostasis that it comprises two 
percent of the total protein in the Müller glia, a level that decreases with age (Paasche et al., 
1998). As oxidative stress increases in glaucoma (Tezel et al., 2005;  Wang et al., 2005), 
endogenous antioxidants are likely insufficient to maintain redox homeostasis.  
Our first efforts at decreasing oxidative stress in glaucoma delivered exogenous lipoic acid, 
an organosulfur compound also made by mitochondria, over several months to DBA/2J 
mice with glaucoma. Lipoic acid protected RGCs from cell death and improved retrograde 
transport; indices of anti-oxidant activity were also increased (Lambert et al., 2008). In 
researching the mechanism of lipoic acid neuroprotection, we determined that the 
compound was working through the transcription factor Nrf2. In other contexts, lipoic acid 
was able to restore GSH levels in the aged liver by increasing Nrf2 nuclear translocation and 
its binding to the anti-oxidant response element (Suh et al., 2004). Nrf2 overexpressing 
astrocytes, when cocultured with motor neurons expressing mutant hSOD1, protected the 
neurons from cell death through GSH-enabled reduction of ROS (Vargas et al., 2008). These 
data demonstrate that increasing Nrf2-ARE activity decreases ROS generation through 
upregulation of anti-oxidant enzymes. We hypothesized that Nrf2 activation in retinal glia 
could provide additional anti-oxidant capacity to the retina, thereby protecting RGCs from 
pressure and ischemia-induced cell death. First, we subjected GCLM knockout mice, which 
have just 10 to 15 percent of their normal production of glutathione (Yang et al., 2002), to 
acute glaucoma. GCLM-/- mice with glaucoma experienced a significant increase in RGC 
death and decreased retrograde axon transport in the remaining RGCs compared to 
wildtype littermates. This implicated glutathione as important to RGC survival in glaucoma. 
Our next experiments will target astrocytes and Müller glia to overexpress Nrf2. Glaucoma 
will provide the initial stimulus for Nrf2 activation, but the additional transcripts will 
enhance Nrf2 promotion of anti-oxidant genes.  
6. Conclusions 
Glaucoma is a complex disease. Diverse etiology has challenged researchers to determine 
disease mechanism, and several hypotheses have provided exciting ideas about how to 
www.intechopen.com
 
Manipulating Glia to Protect Retinal Ganglion Cells in Glaucoma 41 
achieve neuroprotection. The latest research supporting the symbiotic relationship of 
neurons and glia suggest the pursuit of glial manipulation as a worthwhile means to protect 
RGCs in glaucoma.  
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